|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
ENHANC3D GENOMICS Awarded QuickFire Challenge Grant |
 |
|
Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge. The Challenge called for innovative companies with transformative potential solutions aiming to advance precision medicine approaches in immune-mediated disease. Enhanc3D will receive grant funding, one year of residency at Johnson & Johnson Innovation – JLABS, and mentorship from experts at the Johnson & Johnson Family of Companies.
Founded in 2020, Enhanc3D was spun out of Professor Peter Fraser’s pioneering 3D genome organisation research laboratory at the Babraham Institute in Cambridge, UK. Enhanc3D’s mission is to unlock the full potential of the human genome’s 3D organisation for target and biomarker discovery. Current identification methods are limited to linear genome sequences and therefore are unable to capture the complexity of 3D genomic interactions which underpin cell states in health and disease. Enhanc3D’s proprietary disruptive technology focuses on the uncharted non-coding regions that make up 98% of the human genome to identify 3D genetic interactions that are causal for disease susceptibility and progression.
Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: “Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTM to enable breakthroughs in precision medicine. Enhanc3D’s 3D genome atlas of different immune and neuronal cell types has the potential to transform target, pathway and patient signature identification. We are thrilled to be recognized among the Awardees and look forward to expanding our human 3D genome atlas within the network of world-leading scientists, clinicians and selected strategic partners.”
Enhanc3D closed a seed round in 2021 backed by Bioqube Ventures, StartCodon and two private investors.
Debbie Dumont, Managing Partner at Bioqube Ventures, said: “At Bioqube Ventures, we invest in exciting science that can be advanced into breakthrough therapies. We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator. Enhanc3D has matured from our Create Model into a portfolio company and is now attracting additional financing to launch the GenLink3DTM platform in immune mediated and neurodegenerative diseases.”
The GenLink3DTM platform enables unique high-resolution mapping of DNA interactions in 3D space and advanced computational capabilities that integrate other multiOMIC datasets to produce a functional atlas of healthy and disease-specific genetic signatures. These previously uncharted interactions and AI driven functional genomic insight enables identification of novel pathways, drug targets and biomarkers furthering precision medicine. Enhanc3D’s Founding Team has published their findings in over 40 peer-reviewed articles in internationally leading scientific journals.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Innovative Trials Appoints First Commercial Vice President to Drive Business Growth Worldwide
Innovative Trials, a globally-focused company specializing in clinical
trial patient recruitment, retention and engagement, has appointed
Eloise Moffett to drive forward commercial activity in the US and
beyond.
More info >> |
|
 |
White Papers |
 |
|
Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs
World Courier
With a fully integrated GxP-compliant transport, storage and
distribution system in place and over 140 wholly owned ISO 9001 -
certified offices in more than 50 countries, WORLD COURIER, an
AmerisourceBergen® company, is the world’s largest and most experienced
provider of specialty courier services. It is uniquely positioned to
meet the most demanding industry requirements for managing the global
distribution of time - and temperaturesensitive pharmaceutical products
and IMPs used commercially or in clinical trials.
More info >> |
|
 |
Industry Events |
 |
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)
12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical
companies of manufacturing, primary and secondary packaging, purchasing,
and supply chain and procurement sectors, CMOs and CDMOs leaders, heads
from government and institution on 12-13, June, 2023 in Geneva,
Switzerland.
More info >> |
|
|
